Skip to main content
Premium Trial:

Request an Annual Quote

$50 Million Burrill-Bayer VC Fund Now to Close By End-2002

NEW YORK, Aug. 29 - A biotech venture capital fund launched in January by Burrill & Company and Bayer Diagnostics has secured half of the $50 million originally slated to close by June.


Steven Burrill, CEO of the eponymous merchant bank, today said the fund is now expected to close by the end of the year.


Bayer Diagnostic and Burrill & Company said they formed the fund, called the Burrill Diagnostics Capital Fund, to back new pharmacogenomic- and proteomic-based diagnostic research.


The fund will focus on high-growth areas such as device miniaturization, pharmacogenomic testing, and non-invasive testing, Bayer Diagnostics president Rolf Classon said in a statement in January.


Burrill and Bayer also mentioned as targets technologies that allow for disease-susceptibility genotyping and tools for genetic stratification of patients in clinical trials.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.